Lavipharm S A : further enhances its product portfolio in Urology

Peania, 1 February 2023 - Lavipharm continues to expand its product portfolio in the Greek market by adding one more pharmaceutical product in the category of Urology. It is a fixed combination of dutasteride and tamsulosin addressing the symptoms of benign prostatic hyperplasia (BPH). Lavipharm's new investment further enhances its presence in this therapeutic category.

More specifically, the prescription drug is indicated for the treatment of moderate to severe symptoms of an enlarged prostate gland, aiming to reduce the risk of acute urinary retention and of invasive procedures. According to the American Urological Association, BPH is defined histologically as a disease process characterized by stromal and epithelial cell hyperplasia beginning in the periurethral zone of the prostate and affects more than 60% of men over 60 years old.

BPH can cause problems with urinating, such as a need to urinate often and/or during bedtime (nocturia), but also difficulties when starting to urinate, intermittent urination, urgent urination, a weak stream when urinating, or a feeling of not being able to empty the bladder completely, etc. The result of these symptoms is, among others, that both the quality of life, due to poor sleep quality, and the daily activities of the patient are negatively affected.

Mr. Aristides Polyvos, Head of Marketing Rx & Oncology at Lavipharm Hellas, commented: "The addition of Prostatyl expands the therapeutic options available for maintaining prostate health, always aiming to improve quality of patients' life. Our investment in Prostatyl is part of Lavipharm's strategic plan for the continuous expansion of our product portfolio. With Prostatyl, we offer 6 pharmaceutical options in the area of Urology which cover a wide range of symptoms, acting either in combination or as stand-alone treatments".

With a history of over a century, Lavipharm has been active in the pharmaceutical arena since 1911, always aiming to assist healthcare professionals in their everyday practice, providing them with reliable therapeutic options. Its portfolio includes innovative and effective products that meet patients' daily needs.